On January 12, 2026, WuXi Biologics (Cayman) Inc. presented at the 44th Annual J.P. Morgan Healthcare Conference, underscoring its strategic priorities for 2026. CEO Dr. Chris Chen outlined plans to expand the company’s contract manufacturing footprint by commissioning two additional biologics drug substance facilities in China by Q3 2026, bringing the total global network to 17 sites. He highlighted a 25% year-over-year increase in signed development and manufacturing agreements through December 2025, driven by demand for pre-filled syringe (PFS) solutions and dual-chamber formats. Dr. Chen also revealed that the firm forecasts a 30% rise in commercial drug product volumes for international clients this year, supported by recent capacity expansions in Europe and North America.

WuXi Biologics announced that two of its Wuxi facilities—Drug Product Facility 5 (DP5) and the Drug Product Packaging Center (DPPC)—received GMP certifications from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for commercial manufacturing of an ophthalmic biologic. Both facilities passed a four-day inspection with zero critical findings, reflecting the company’s 100% regulatory inspection success rate. DP5, the group’s first commercial PFS site, and DPPC, which offers customized packaging compliant with international traceability codes, together provide end-to-end drug substance and drug product services. The company’s global drug product capacity now exceeds 100 million units per year, covering liquid, lyophilized and combination products. As of December 2025, WuXi Biologics has passed 46 regulatory inspections—22 by FDA and EMA—and holds 136 facility licenses, reinforcing its position as a preferred CRDMO for biologics development and manufacturing.